Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation

贵金属，如钯或金，可以被植入肿瘤的精细切片，目的是激活癌症组织内的化疗药物，从而减少它们的副作用。针对肿瘤表面抗原的抗体的开发被作为一种新的靶向策略进行研究，目的是促进药物仅在肿瘤部位以受控方式释放。Unciti-Broceta小组建议使用非生物金属钯开发抗体-钯结合物(钯-生物结合物或钯-免疫结合物)作为催化癌症靶向抗体，以通过临床抗癌药物(前药物)的局部释放来杀灭癌细胞/肿瘤。

Precious metals such as palladium or gold can be implanted finely sliced into tumours with the aim of activating chemotherapeutic drugs within the cancerous tissue, thus reducing their side effects. The development of antibodies directed towards tumour surface antigens is investigated as a novel targeted strategy with the aim to promote the release of drugs in a controlled manner exclusively at tumour sites. The Unciti-Broceta Group propose the use of palladium, an abiotic metal, to develop Antibody-Palladium Conjugates (Pd-bioconjugate or Pd-Immunoconjugate) as catalytic cancer targeted antibodies in order to kill cancer cells/tumors by the localised release of clinical anticancer agents (prodrugs).